PARAMUS, NJ, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), announces it will be presenting a late-breaking abstract on new data for PLX-200, an investigational therapy for the treatment of Krabbe disease (globoid cell leukodystrophy) at the 22nd Annual WORLDSymposium™, held February 2-6, 2026 in San Diego, Calif. These data support the contin ...

Regulated information Paris, February 2, 2026 DISCLOSURE FISCAL 2026/13 OF TRANSACTIONS ON TREASURY SHARES Period of: January 26 to January 30, 2026 Issuer: Pluxee N.V. Class of Securities: Ordinary shares (ISIN NL0015001W49) Aggregate presentation by day and by market. Issuer CodeTransaction dateISIN CodeDaily total volume (in number of shares)Daily weighted average price of shares acquiredPlatform213800RQNIQT48SEEO8526-Jan-26NL0015001W4945 78311,1310XPAR213800RQNIQT48SEEO8526-Jan-26<td style="width:98.8 ...

Core Insights - Protalix Bio Therapeutics (PLX) has announced a significant regulatory and clinical milestone for its Fabry disease treatment in Europe, indicating positive progress in its drug development efforts [1] Company Overview - Protalix Bio Therapeutics is focused on developing innovative therapies, particularly in the biotechnology sector, with an emphasis on unique mechanisms of action and first-in-class therapies [1] Market Context - The biotechnology sector is characterized by breakthrough science that can lead to substantial returns, but it also requires careful scrutiny due to inherent risks [1]

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March 2026 If approved by the EC, this dosing regimen would reduce the burden to eligible adult patients, their families and the broader healthcare system due to the current requirement to visit infusion centres or have home infusions every-2-weeks for treatment PARMA, Italy and CARMIEL, Israel, Jan. 30, 2026 (GLOBE N ...

Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March 2026 If approved by the EC, this dosing regimen would reduce the burden to eligible patients, their families, and the broader healthcare system due to the current requirement to visit infusion centres every two weeks for treatment This dosing regimen for Elfabrio is not approved in the U.S. In the U.S., the appr ...

Regulated information Paris, January 26, 2026 DISCLOSURE FISCAL 2026/12 OF TRANSACTIONS ON TREASURY SHARES Period of: January 19 to January 23, 2026 Issuer: Pluxee N.V. Class of Securities: Ordinary shares (ISIN NL0015001W49) Aggregate presentation by day and by market. Issuer CodeTransaction dateISIN CodeDaily total volume (in number of shares)Daily weighted average price of shares acquiredPlatform213800RQNIQT48SEEO8519-Jan-26NL0015001W4949 76011,3457XPAR213800RQNIQT48SEEO85<td style="width:90.4219px;;te ...

Group 1 - Pluxee N.V. disclosed transactions on treasury shares for the period from January 12 to January 16, 2026 [1] - The total volume of shares acquired daily varied, with notable transactions on January 12, 13, 14, 15, and 16, 2026 [2] - The weighted average price of shares acquired showed a downward trend over the specified period, starting from €12.4396 on January 12 to €11.3665 on January 16 [2] Group 2 - Pluxee operates in 28 countries and specializes in Employee Benefits and Engagement, providing solutions across various sectors including Meal & Food, Well-being, and Reward & Recognition [3] - The company has over 5,600 engaged team members and serves more than 500,000 clients, impacting over 37 million consumers and 1.7 million merchants [3] - With over 45 years of experience, Pluxee is committed to creating a positive impact on local communities and supporting employee well-being [3]

Core Insights - Pluxee N.V. disclosed transactions on treasury shares for the period from January 5 to January 9, 2026, indicating ongoing share buyback activities [1]. Group 1: Treasury Share Transactions - On January 5, 2026, a total of 50,331 shares were acquired across three transactions at average prices of €12.9902, €12.9517, and €12.7300 on different platforms [2]. - On January 6, 2026, 55,000 shares were acquired at average prices of €12.9968 and €12.9878 [2]. - On January 7, 2026, 60,000 shares were acquired at average prices of €13.1981, €13.1505, and €13.1063 [2]. - On January 8, 2026, 62,000 shares were acquired at average prices of €12.7871, €12.7765, and €12.7103 [2]. - On January 9, 2026, 64,000 shares were acquired at average prices of €12.7505, €12.7363, and €12.7400 [2]. Group 2: Company Overview - Pluxee operates in 28 countries, focusing on Employee Benefits and Engagement, providing solutions in Meal & Food, Well-being, Lifestyle, Reward & Recognition, and Public Benefits [3]. - The company has over 5,600 engaged team members and serves more than 500,000 clients, 37 million consumers, and 1.7 million merchants [3]. - With over 45 years of experience, Pluxee aims to create a positive impact on local communities and support employee well-being while being environmentally conscious [3].

Regulated information Half-year report on Pluxee N.V.’s liquidity contract as of December 31, 2025 Issy-les-Moulineaux, France, January 8, 2026 Pursuant to the liquidity contract entered into by Pluxee N.V. with BNP Paribas, the following assets appeared on the liquidity account as of December 31, 2025: 223,196 Pluxee N.V. ordinary shares€6,037,935 For the second half of 2025, during the period from July 1, 2025, to December 31, 2025, the following transactions were performed: Purchasing of 444,312 ordina ...